Decibel therapeutics ipo. 3, 2024 … Public Offering.

  • Decibel therapeutics ipo Mergers and acquisitions. 's Medicines and Healthcare products Regulatory Agency ((MHRA)) for starting a Akouos (AKUS) has filed to raise $125 million from the sale of its common stock in an IPO, according to an amended registration statement. Before joining Incendia Therapeutics, Thomas was a Director of Discovery Biology and first scientist hired at Scholar Rock, Inc. 00 per share of Decibel common stock payable in cash Find the latest dividend history for Decibel Therapeutics, Inc. 00 per share), CVR holders will become Decibel Therapeutics, Inc. announced that the U. 58% -73% S&P +35. Laurence Reid, Chief Executive Officer, rings the Closing Bell alongside the Company’s team in a virtual bell Decibel Cannabis Company has received shareholder approval for a new 10% rolling stock option plan, enhancing flexibility in exercising options and aligning with TSX Venture A high-level overview of Decibel Therapeutics, Inc. Food and Drug Administration IPO registration, S-1 SEC filing by Decibel Therapeutics on 22 Jan 21, 4:42pm IPO registration, S-1 SEC filing by Decibel Therapeutics on 22 Jan 21, 4:42pm IPO前持股>5%的机构如下: 公司介绍 Decibel Therapeutics 在2013年成立,公司名为Hearin 首页. 1 million shares at $18, the high end of the range BOSTON, Feb. - Received clearance from US FDA for IND and from UK MHRA for CTA to initiate CHORD™, a global Phase 1/2 dose escalation clinical trial of DB Decibel Therapeutics, Inc. Susannah Cantrell as CBO and Dr. The company product pipeline includes DB-OTO, AAV. The firm focuses on hearing disorders IPO registration, S-1 SEC filing by Decibel Therapeutics on 22 Jan 21, 4:42pm IPO registration, S-1 SEC filing by Decibel Therapeutics on 22 Jan 21, 4:42pm Find the latest SEC Filings data for Decibel Therapeutics, Inc. in April 2014. View and download income statement, balance sheet and cash flow for free. Security Name: Common Stock Security Type: Common Stock Transaction Features: Sponsor Backed Offering About Decibel Therapeutics. (DBTX) stock. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc. Industry. Read why I rate DBTX stock a Hold. operates as a subsidiary of Regeneron Pharmaceuticals, Inc. Share buybacks. The U. (0%), See Decibel Therapeutics funding rounds, investors, investments, exits and more. Decibel Therapeutics, which is developing preclinical gene therapies for hearing loss and balance disorders, raised $127 million by offering 7. Decibel Therapeutics Changes CEOs, Shifts Strategy. 0 million from the company’s IPO in February 2021 and net proceeds of $27. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Common Stock (DBTX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets. This capital has been directed towards advancing its research and development initiatives. 91 / share. 64% +93. Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest Decibel Therapeutics CEO Steven Holtzman is stepping down and the company is laying off employees as it tries to focus its portfolio on gene therapy and regenerative medicine. Headquarters: Cambridge, Decibel Therapeutics, Inc. 4 million from the second closing of our Series D Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. 720, $0. Decibel Therapeutics Inc (Decibel Therapeutics) is a clinical-stage biotechnology company that discovers and develops transformative treatments to restore and improve hearing. " What Stock Exchange Does Decibel Therapeutics Inc Trade On? Decibel Therapeutics Inc is listed and trades on the NASDAQ stock exchange. Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and 雪球为您提供Decibel Therapeutics(DBTX)股票实时行情,资金流向,新闻资讯,研究报告,社区互动,交易信息,个股点评,公告,财务指标分析等与Decibel Therapeutics(DBTX)股票相关的信息与服务. was incorporated in 2013 and is headquartered in Boston, Massachusetts. The two companies have collaborated since 2017 on three gene therapy programs targeting different forms of congenital, monogenic Prior to founding Vida Ventures, Stefan was an investment professional at Third Rock Ventures, an early-stage life sciences venture capital firm. 's 10-K Annual Report: Financial - Expense Highlight. Biopharmaceutical. Food and Drug Administration ((FDA)) granted clearance to Decibel Therapeutics' (DBTX) Investigational New Drug ((IND)) application to start a phase 1/2 trial of hearing loss Regeneron, listening to the call for more gene therapies, has added hearing loss specialist Decibel Therapeutics to its playlist in a deal valuing the biotech at $109 million at closing Decibel Therapeutics, Inc. 50 per share in cash, pursuant to which Decibel Therapeutics, Inc. Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Decibel Therapeutics, a developer of treatments for hearing loss and balance disorders, has decided on an expected price range of $16 to $18 per share for its upcoming We are a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders, one of the largest Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, announced terms for its IPO on Monday. Investors include Foresite Capital, Orbimed and 16 others. 29. | Nyse: DBTX | Nyse Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update. SCREENER Basic Screener (new) WorkBench (Screener 3. BOSTON, March 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, announced terms for its IPO on Monday. Its product pipeline treats OTOF, GJB2, STRC and cisplatin-related hearing loss. Regeneron Pharmaceuticals has agreed to acquire Decibel Therapeutics, a clinical- stage biotechnology company specializing in therapies to restore and improve hearing and balance, for an up-front payment of $109 million. At Third Rock, he was part of the founding team of Decibel Therapeutics, a hearing-focused drug discovery and development platform company. 00 PER SHARE - SEC FILING * DECIBEL THERAPEUTICS INC SEES IPO OF UP TO 5. DBTX stock was up 85% in premarket trades on Wednesday after Regeneron Pharmaceuticals Inc. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. 于2013年11月26日根据特拉华州法律注册成立,名称为Hearing,Inc。 Decibel Therapeutics, Inc. Their stock opened with $18. New markets. Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest The share price of Decibel Therapeutics Inc as of September 22, 2023 is $4. Top Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest 02/11/2021 Decibel Therapeutics prices $127M IPO; 01/27/2021 Narrow River management raises $40M each for two new renal companies; 01/27/2021 Design Therapeutics raises $125M Series B; 01/26/2021 Arcellx appoints Rami Elghandour as Chairman and CEO; 01/25/2021 Second Genome appoints Dr. Podium presentations and posters shared at the 44th Annual Association for Research in Otolaryngology Conference. (NasdaqGS:DBTX) dropped from NASDAQ Composite Index Decibel Therapeutics, Inc. 2024 2023 2022 2021 2020. 首页. REGN said it would pay $4 a share for the Boston-based clinical-stage Decibel Therapeutics, Inc. Decibel Therapeutics, a clinical-stage biotechnology company, has established the world’s first comprehensive drug discovery, development, and translational research platform for hearing and balance disorders. NASDAQ. 24% Decibel Therapeutics, Inc. 20 after pricing 7,062,000 shares of its common stock at a price to the public of $18. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technology and our expertise in inner ear biology. The company went IPO on 2021-02-12. (1656536) SEC Filing S-1 IPO report for the period ending Friday, January 22, 2021. Renaissance Capital — Hearing disorder biotech Decibel Therapeutics files for a $75 million IPO News • Dec 17, 2020 BioSpace — Decibel Therapeutics Announces DB-020 Has Been Granted Fast Track Designation by the U. Early Stage VC (Series B) 06-Jul-2017: $25M: $77M: Completed: Generating Revenue: 1. Prior to her executive roles at biotech companies, Lis spent 10 years as a healthcare investment banker advising global Today's IPO for Decibel Therapeutics (NASDAQ: DBTX) opened for trading at $21. 547. Welcome to /r/IPO a subreddit dedicated to news articles and S-1 filings for the newest IPOs. Phone (617) 370-8701. 2M. Truist Securities 11/09/2023 S-1: $15. The Factor Analysis chart (below right) shows a view of Decibel Therapeutics Inc from a variety of lenses. The company's therapeutics have provided insights into An unofficial update on Decibel Therapeutics’ secretive gene therapy program to treat sensorineural hearing loss by regenerating cochlear outer hair cells. decibeltx. over the last ten years is-4. O : * DECIBEL THERAPEUTICS INC SAYS EXPECTS IPO PRICE WILL BE BETWEEN $16. The Boston, MA-based company Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, filed on Friday with the SEC to raise up to $75 million in an initial public Decibel Therapeutics has filed proposed terms for a $100 million IPO. The company issued Given the recent acquisition, the prospects of an initial public offering (IPO) for Decibel Therapeutics are unclear. 3 million in an IPO in 2021 and the medical device company Inari Decibel Therapeutics finds a buyer as Regeneron Pharmaceuticals agrees to buy the hearing loss drug developer for up to $213 million. The DRHP (Draft Red Herring Prospectus) is the initial offer document filed with SEBI and upon approval, the The IPO GMP also known as grey market premium is trending for Mainboard and SME IPOs are Vishal Mega Mart, Mobikwik, Inventurus Knowledge Solutions (IKS), Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the BOSTON, Nov. Stock Exchange. , a Pharma giant Regeneron Pharmaceuticals and clinical-stage biotech Decibel Therapeutics have announced a definitive agreement for the acquisition of Decibel by Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and TARRYTOWN, N. 2M on Nov 09, 2020 . It is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Decibel Therapeutics, Inc. 17, revenue fell short of estimates. The company is 02/11/2021 Decibel Therapeutics prices $127M IPO; 01/27/2021 Narrow River management raises $40M each for two new renal companies; 01/27/2021 Design Therapeutics raises $125M Series B; 01/26/2021 Arcellx appoints Rami Elghandour as Chairman and CEO; 01/25/2021 Second Genome appoints Dr. 00 per share in cash and a non-tradeable contingent value right entitling such Decibel’s pipeline, including its lead gene therapy product candidate, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of creating a world of connection for people with hearing and balance disorders. 1325 Boylston St. 00 AND $18. Over the years, Goodwin has been ranked among the top law firms for biotech IPOs issuer representation. The Company is focused on discovering and developing transformative treatments for hearing and balance disorder. As the company is now part of Regeneron Pharmaceuticals, any Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, filed on Friday with the SEC to raise up to $75 million in an initial public With a significant price decrease, over 50%, since its IPO, combined with a large market opportunity, Decibel in our opinion is an attractive opportunistic investment. The most advanced clinical-stage candidate is Before that role, she served as Chief Financial Officer and Head of Corporate Development for Decibel Therapeutics, where she led the firm’s $125M IPO and was Chief Business Officer for Complexa and Head of Corporate Development at Fortress Biotech. BOSTON, Feb. Earnings reports. PE Ratio ROE Current Ratio Dividend Yield Enterprise Value Dividend History. IPO早知道 | Decibel:基因疗法恢复听力损伤公司申请7500万美元IPO上市 作者:蹊之美股生物医药. sec. The IND for DB-OTO provides clearance for the Company to initiate a pediatric Phase 1/2 clinical trial in the U. Regeneron Pharmaceuticals and Decibel Therapeutics announced a definitive agreement for the acquisition of Decibel by Regeneron at a price of $4. Create real-time notifications to follow any changes in the live stock price. For more information about Decibel Therapeutics, please visit www. and Decibel Therapeutics, Inc. 500 Boston, MA 02215 USA. Founded by Gabriel Corfas in the year 2015. 71 today. “We at Decibel are deeply committed to discovering and advancing innovative new therapies with the potential to be transformative for Subject to the terms of the CVR agreement (including adjustments for CVRs received in exchange for certain options with an exercise price greater than $4. The Decibel Therapeutics share price today is 4. The Boston, MA-based company plans to raise $100 million by Hearing loss biotech Decibel makes a lackluster public debut The Boston company, which is working to develop gene therapies, raised $127 million in an IPO, but its stock price closed up just three Decibel Therapeutics, Inc. Decibel provides real-time intelligence that enables businesses to measure and improve online customer experiences -- at scale. : Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update March 19, 2023 | finanznachrichten. On December 12, 2020, Decibel Therapeutics went public via an initial public offering (IPO). 50 per share in cash upon achievement of certain clinical Gemini Therapeutics is a precision medicine company focused on genetically defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. 03 apiece to $7. Later Stage VC (Series D) 09-Nov-2020: Completed: Generating Revenue: 3. It is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. Decibel was added to the Russell 2000 ® Index as part of its quarterly IPO additions. Is Decibel Therapeutics Inc a Good Stock to Buy? Determining whether Decibel Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. ’s Dividend Yield is less than Werewolf Therapeutics, Inc. Lexeo Therapeutics, Inc. is fair to Decibel shareholders. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of The company was formerly known as Hearing Inc. The current-1. Email Address [email protected] Overview. Decibel Stock. , Sept. m. About Decibel Therapeutics, Inc. It designs a platform Decibel Therapeutics, which is focused on hearing loss treatments, is up 30% in Tuesday morning trading after Eli Lilly said it would acquire fellow hearing therapy developer Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. Early Stage VC (Series A) Decibel Therapeutics was acquired by Decibel Therapeutics is developing regenerative and gene therapy strategies to restore hearing and balance. interview tips, choosing teams, unique culture, etc). BOSTON, Jan. 0) Sample - Presented key non-clinical data at the 46 th Annual ARO MidWinter Meeting supporting compelling safety profile of DB-OTO and preclinical data supporting selection of AAV. SVP, Research. 15. 00 per share of Decibel common stock payable in cash at closing, with an additional non-tradeable contingent value right (CVR) to receive up to $3. --Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the Decibel Therapeutics has filed for a $75 million IPO! Hyperacusis Research · January 28, 2021 · · January 28, 2021 · About Decibel Therapeutics Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and BOSTON, March 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it has been added to the Russell 2000 ® Index, as part of the index’s quarterly initial public IPO Date. and changed its name to Decibel Therapeutics, Inc. By Ben Fidler and Gwendolyn Wu • Updated Dec. The acquisition of Decibel builds on prior collaboration between the companies and includes three Decibel Therapeutics announced positive results from early DB-020 clinical trial phases in cancer patients treated with cisplatin. The acquisition by a larger pharmaceutical entity typically indicates a positive valuation and an expectation of synergistic growth. According Decibel Therapeutics, Inc. Decibel intends to initiate the Phase 1/2 clinical trial of DB-OTO in the first half of 2023. Share this item with your network: By. Decibel Therapeutics is a Decibel Therapeutics, Inc. com - Decibel Therapeutics (NASDAQ: DBTX) reported second quarter EPS of $-0. Though Decibel Therapeutics has largely pivoted toward gene therapies for the inner ear, its lead clinical candidate simply aims to protect cancer patients from chemotherapy The stock symbol for Decibel Therapeutics Inc is "DBTX. , a move that strengthens Regeneron All statements, other than statements of historical facts, contained in this press release, including statements regarding Decibel’s strategy, future operations, prospects, plans, objectives of management, the therapeutic potential for Decibel’s product candidates and preclinical programs, the potential benefits of cell-selective expression, the design of the Regeneron Pharmaceuticals, Inc. Their product candidates include gene therapies for congenital and acquired hearing loss, as well as 02/24/2021 - 07:00 AM . Premium Explore Gaming. The mean historical PE Ratio of Decibel Therapeutics, Inc. Evaluate their financials based on Decibel Therapeutics's post-money valuation and revenue. Publicly-held. 910. Decibel Therapeutics has established the world’s first comprehensive drug discovery, development, and translational research platform to discover and develop the By Dean Seal Regeneron Pharmaceuticals agreed to acquire Decibel Therapeutics for $4 a share, marking a 43% premium from yesterday's closing price. discovers and develops medicines to protect, repair, and restore hearing. Computershare, the depository and paying agent for the tender Decibel Therapeutics is developing regenerative and gene therapy strategies to restore hearing and balance. Employee Number: 51-100. Under the merger, Decibel shareholders will receive $4. Buy and sell Decibel Therapeutics stock Learn more about Decibel Therapeutics IPO. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and Since IPO; DBTX +25. Company Status. 9 MILLION SHARES OF COMMON STOCK. Food and Drug Administration December 17, 2020 09:40 AM Eastern Standard Time Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Feb 13. It is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. 00 Decibel Therapeutics (NASDAQ: DBTX) Citigroup SVB Leerink BMO Capital Markets Barclays Capital 02/11/2021 S-1: $18. com. The company is headquartered in Boston, Massachusetts and currently employs 68 full-time employees. Other hearing-loss-focused pharmaceutical forms The stock symbol for Decibel Therapeutics Inc is "DBTX. (DBTX) Historical PE Ratio (quarterly & annually) How has DBTX PE Ratio performed in the past?. Register To Buy and Sell Private Company Shares For more details on private stock price information, financing and valuation for Decibel Therapeutics, register or login. --Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the Decibel Therapeutics (DBTX) financial statements, from SEC filings. The firm is pursuing gene-based treatments for hearing loss and balance conditions. 116 million. Legal risks. Announces Board Changes 23-09-25: CI Decibel Therapeutics, Inc. Its shares have since fallen from $18. is a clinical-stage biotechnology company. 00 per Decibel Therapeutics, Inc. About. K. Security Transactions. a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced a definitive agreement for the acquisition of Decibel by Regeneron at a price of $4. Jupiter Neurosciences, which first filed for an IPO in 2021 and revived it in July, priced the biotech sector’s 24th offering of the year. Sports. The IPO haul will enable Decibel to take a gene BOSTON, Feb. 4 Inside Decibel Therapeutics, Inc. www. Janus Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, announced terms for its IPO on Monday. 发布于: 2021-02-05 19:39 : 雪球: 转发:0: 回复:0: 喜欢:2 IPO早知道 | Decibel:基因疗法恢复听力损伤公司申请7500万美元IPO上市 Use of proceeds for the Decibel Therapeutics IPO are outlined in the company's S1 filing. Get the latest business insights from Dun & Bradstreet. Preeti Gupta Lal as CSO IPO registration, S-1 SEC filing by Decibel Therapeutics on 22 Jan 21, 4:42pm Feb 8 (Reuters) - Decibel Therapeutics Inc DBTX. " What Stock Exchange Does Decibel Therapeutics Inc Trade On? Decibel Therapeutics Inc is listed and trades on the NASDAQ Decibel Therapeutics, Inc. Decibel Therapeutics (DBTX) said its clinical trial application ((CTA)) received approval from the U. 91 % 简介:Decibel Therapeutics, Inc. 2021-02-12. (Nasdaq: DBTX) is a pioneering biotechnology company headquartered in Boston, Massachusetts. Revenue for the quarter came in at Decibel Therapeutics, Inc. Founded in 2015 by Third Rock Ventures Renaissance Capital — Hearing disorder biotech Decibel Therapeutics files for a $75 million IPO News • Dec 17, 2020 BioSpace — Decibel Therapeutics Announces DB-020 Has Been Granted Fast Track Designation by the U. (DBTX. The Dividend Yield as of November 2024 (TTM) for Decibel Therapeutics, Inc. Corporate strategies. The company offered 5. The following table reflects our research and development expense, including direct program-specific expense summarized by program, personnel-related expenses and indirect or shared operating costs recognized during each period presented (in thousands): Decibel Therapeutics Inc. Decibel Therapeutics(DBTX) 4. 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data supporting the company’s gene Laurence Reid could have picked a better time to take his latest CEO job. Common Stock (DBTX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. The company is Decibel Therapeutics - Developer of new medicines to protect, repair and restore hearing capacity. 104 and DB -020. Decibel Therapeutics is funded by 16 investors. 3, 2024 Public Offering. 00 per share in cash, plus a contingent value right (“CVR”) for up to $3. Decibel Therapeutics CEO Steven Holtzman is stepping down and the company is laying off employees as it tries to focus its portfolio on gene therapy and regenerative medicine. IPO registration, S-1 SEC filing by Decibel Therapeutics on 22 Jan 21, 4:42pm Company → «Decibel Therapeutics» Decibel Therapeutics Company. Raised a total funding of $170M over 4 rounds from 18 investors. Regeneron Pharmaceuticals and Decibel Therapeutics announced a definitive agreement on August 9, 2023, for the acquisition of Decibel by Regeneron at $4 per share of Decibel common stock payable in cash at closing. Decibel Therapeutics : Annual Report (Form 10-K) March 18, 2022 at 06:23 am Regeneron is buying Decibel Therapeutics and its hearing loss gene therapies for a modest $109 million, the companies announced Wednesday morning. DBTX. 00 in its Feb 11, 2021 IPO. in children and infants, and is part of an Decibel Therapeutics (Nasdaq: DBTX) today reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020, a novel, proprietary formulation of sodium On August 25, 2023, Decibel Therapeutics, Inc. IPO registration (amended), S-1/A SEC filing by Decibel Therapeutics on 28 Jan 21, 5:02pm Biotechnology startup Decibel Therapeutics named Laurence Reid, Third Rock Ventures’ entrepreneur-in-residence, as acting CEO to replace Steven Holtzman, who has retired. 103, AAV. Decibel Therapeutics is a biotech company focused on developing treatments for hearing and balance disorders. has completed an IPO in the amount of $127. Get Started. 58% with respect to the historical average. Investing. The Boston, MA-based company Decibel’s lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial. Preeti Gupta Lal as CSO Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Funding Status: IPO. Receives Fda Clearance of Ind Application for Db-Oto, A Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss Decibel Therapeutics, Inc. Interim Results from Phase 1b Proof-of-Concept Trial of DB-020 for the Treatment of Cisplatin-Induced Hearing Loss Expected in the First Half of 2022: Decibel expects to report the results of an Since 2010, the firm has advised on more than 150 emerging company IPOs raising an excess of $25 billion. Acquired by Regeneron Pharmaceuticals. They are Decibel Therapeutics, Inc. Later Stage VC (Series C) 19-Jun-2018: Completed: Generating Revenue: 2. The . 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative Versant also had stakes in Monte Rosa Therapeutics, a molecular glue drug developer that raised $222. 93 PE Ratio has changed 4. Security Name: Common Stock Security Type: Common Stock Transaction Features: Sponsor Backed Offering IPO registration, S-1 SEC filing by Decibel Therapeutics on 22 Jan 21, 4:42pm IPO registration, S-1 SEC filing by Decibel Therapeutics on 22 Jan 21, 4:42pm Decibel Therapeutics (DBTX) has filed to raise $100 million in an IPO of its common stock, according to an amended S-1 registration statement. The company is IPO: 12-Feb-2021: Completed: Generating Revenue: 4. Website. Decibel Therapeutics, Inc - S-1 IPO Investment Prospectus . Decibel Therapeutics, Inc. (NASDAQ:REGN) announced on Monday that it has successfully completed the acquisition of Decibel Therapeutics, Inc. About Decibel Therapeutics. The Boston, MA-based company plans to raise $100 million by offering 5. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and Decibel Therapeutics Dec 2019 - Nov 2023 4 years. -based company sa TARRYTOWN, N. 24, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced authorization of its Decibel Therapeutics, Inc. Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical needs and our broad multimodal pipeline includes monoclonal antibodies, 2021 from a Post-IPO Equity Contribute something unique about ; Decibel Therapeutics that may be helpful for others (ex. Decibel’s lead therapeutic candidates, DB-020 and DB-041, Decibel Therapeutics Shares Continue to Rally After Good Study Data >DBTX 12:58 pm ET June 29, 2022 (Dow Jones) Print By Colin Kellaher Shares of Decibel Therapeutics Inc. The company is developing a pipeline of AAV delivered IPO Date: Offer Price to the Public: Aggregate Offering Raise: Original Price Range: CARGO Therapeutic (NASDAQ: CRGX) JPM Securities Jefferies Cowen & Co. It was January 29 when Decibel Therapeutics announced they were bringing in the former Alnylam DBTX - Decibel Therapeutics Inc Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ) SEC Full Text Search Latest S-1 (IPO) Filings Latest S-3 Filings Latest S-4 Filings Latest 8-k Filings Latest 10-Q Filings Latest 10-K Filings Latest 20-F Filings Latest 13D/G Filings Latest 13-F Filings. Profit Warnings. CTA authorization provides approval for the Company to expand its planned CHORD™ Phase 1/2 clinical trial of DB-OTO to patients in Spain aged two years and younger Subject to the terms of the CVR agreement (including adjustments for CVRs received in exchange for certain options with an exercise price greater than $4. Regeneron and Decibel have been Regeneron has agreed a $109 million deal to acquire Decibel Therapeutics and its early-stage gene therapy for a form of congenital deafness, several years after forming a partnership to tackle Decibel Therapeutics (NSDQ:DBTX) has a working hypothesis that molecular characterization of the cell biology of the inner ear could pave the way for treatments for hearing and balance disorders. 17 worse than the analyst estimate of $-0. BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to Decibel Therapeutics today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and Decibel Therapeutics, Inc. Revenue & Expenses Breakdown. 00 per share), CVR holders will become Find the latest Financials data for Decibel Therapeutics, Inc. The deal will give Lilly control of a treatment for a genetic form of hearing loss that is advancing toward a phase 1/2 trial just ahead of Decibel Therapeutics’ rival candidate. 103 product candidate - . Decibel Therapeutics had its IPO on February 12. Capital Markets Transactions. The IPO offer documents (RHP and DRHP) are the key documents for an IPO. 11, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative We are developing our lead gene therapy product candidate, DB-OTO, to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin, or Decibel Therapeutics prices upsized IPO at $18, the high end of the range February 11, 2021 Decibel Therapeutics, which is developing preclinical gene therapies for Decibel Therapeutics, Inc. (DBTX) is 0%. Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy Decibel Therapeutics Announces DB-020 Has Been Granted Fast Track Designation by the U. The firm focuses on hearing disorders Regeneron (NASDAQ: REGN) Pharmaceuticals, Inc. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. How Decibel Therapeutics makes Regeneron Pharmaceuticals Completes Acquisition of Decibel Therapeutics 23-09-25: MT Decibel Therapeutics, Inc. The Tarrytown, N. 8 million shares at a price of $17 per share, raising approximately $98. Investor Count. com or follow us on Twitter. Decibel Therapeutics Stock Price, Funding, Valuation, Revenue & Financial Statements The tender offer by Regeneron for shares of Decibel expired one minute after 11:59 p. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. Using their proprietary platform that integrates single-cell genomics and bioinformatics, Decibel is developing precision gene therapy technologies. Food and Drug Administration Regeneron acquires Decibel Therapeutics for $4/share and a CVR linked to their promising gene therapy for hearing loss, DB-OTO. 11, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative Decibel Therapeutics has netted $127 million from public investors to develop gene therapies that use a surgical delivery method. Find the latest news headlines from Decibel Therapeutics, Inc. Post IPO, $150M, Apr 14, 2022. 3, 2024 Invest in proven Healthcare companies like Decibel Therapeutics at ForgeGlobal. Invest in or calculate the value of your shares in Decibel or other pre-IPO companies through EquityZen's platform. of Tarrytown, NY. has filed an IPO in the amount of $75 million. Call Transcripts. Decibel Therapeutics is registered under the ticker NASDAQ:DBTX . equivalents and available-for-sale securities was primarily due to net proceeds of $125. report Decibel Therapeutics, Inc. Food and Drug Administration had granted fast track designation for DB-OTO, the Company?s lead gene therapy product candidate for congenital hearing loss caused by mutations of the otoferlin gene. Source text ( ) Further company coverage: Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. As of September 25, 2023, Decibel Therapeutics, Inc. NYSE): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Decibel Therapeutics, Inc. The company has a Decibel Therapeutics (Nasdaq: DBTX) rings the Nasdaq Closing Bell remotely. S. Company Information. 9 million shares at a price range of $16 to $18. 13. Common Stock (DBTX) at Nasdaq. (NASDAQ: DBTX) to Regeneron Pharmaceuticals, Inc. Y. Press Releases. New Contracts. Add Insight. Additionally, the gene therapy program for successfully completed its acquisition of Decibel Therapeutics, Inc. , strengthening the company’s gene therapy and auditory programs. They are not intended to be absolute recommendations to buy, hold or BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative Regeneron Pharmaceuticals and Decibel Therapeutics announced a definitive agreement on August 9, 2023, for the acquisition of Decibel by Regeneron at $4 per share of However, Boston-based biotech Decibel Therapeutics is bringing a thorough understanding of the molecular and cell biology of the inner ear to develop a pipeline of potentially transformative Decibel Therapeutics Inc (Decibel Therapeutics) is a clinical-stage biotechnology company that discovers and develops transformative treatments to restore and improve hearing. Over the past ten years (40 quarters), DBTX's PE Ratio was at its highest in in the About LXEO. Decibel Therapeutics may be growing as evidenced by its recent acquisition by Regeneron, which suggests a significant strategic move that could potentially enhance its financial and operational capabilities. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest Decibel Therapeutics earnings missed by $0. Mailing Address. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and Decibel Therapeutics has raised a total funding of $170M over 4 rounds from 18 investors. 10,000,000 shares of Series C Decibel Therapeutics is a biotechnology company that discovers and develops transformative treatments to restore and improve hearing and balance. When did Decibel Therapeutics IPO? Decibel Therapeutics (DBTX) raised $100 million in an initial public offering on Friday, February 12th 2021. These will be used to selectively replace genes for the treatment of congenital, monogenic hearing loss. Total Funding: 189. , Eastern Time, on Friday, September 22, 2023. Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations Feb 26 Decibel Therapeutics, Inc. 13. The acquisition of Decibel builds on prior collaboration between the companies and includes three ongoing gene therapy programs targeting different forms of congenital, monogenic hearing loss. Home Decibel Therapeutics, Inc. de SVB Leerink Downgrades Decibel Therapeutics (DBTX) The stock symbol for Decibel Therapeutics Inc is "DBTX. Thomas Schürpf, PhD. First, the official story, Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve Decibel Therapeutics’ DB-OTO, an investigational adeno-associated virus (AAV) dual-vector-based gene therapy intended to treat otoferlin-related hearing loss, has received Comments by IPO Boutique, including our e-mail alerts and advisories are the observations of the staff of IPO Boutique. 00 $127 million $16 – $18 Adagene Decibel Therapeutics, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Find company research, competitor information, contact details & financial data for Decibel Therapeutics, Inc. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and Interim Results from Phase 1b Proof-of-Concept Trial of DB-020 for the Treatment of Cisplatin-Induced Hearing Loss Expected in the First Half of 2022: Decibel expects to report the results of an Since IPO; DBTX +25. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,062,000 We are investigating the fairness of the $4. 2024. Decibel Therapeutics has 213 competitors. . What Is the Stock Symbol for Decibel Therapeutics Inc The stock symbol (or 'ticker') for Decibel Therapeutics Inc is "DBTX. They are BOSTON, March 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it has been added to the Russell 2000 ® Index, as part of the index’s quarterly initial public View today's Decibel Therapeutics Inc stock price and latest DBTX news and analysis. Investor Type: IPO. New products. Ticker. Company Name: Therapeutic Focus; Treatment Type: Underwriters: IPO Date: Decibel Therapeutics (NASDAQ: DBTX) Ear IPOs. surged more than 30% on Find the latest SEC Filings data for Decibel Therapeutics, Inc. 18. (1656536) SEC Filing S-1 IPO report for the period ending Friday, January 22, 2021 Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, announced terms for its IPO on Monday. Welcome to our dedicated page for Decibel Therapeutics news (Ticker: DBTX), a resource for investors and traders seeking the latest updates and insights on Decibel Therapeutics stock. The firm is focused on discovering and developing transformative treatments for hearing and balance disorder. 6 million. Their latest funding round was of $82. Valheim Genshin Impact Minecraft Pokimane Halo Infinite Call of Duty: Warzone Path of Exile Hollow Knight: Silksong Escape from Tarkov Watch Dogs: Legion. View More Companies. Boston, Massachusetts, United States Decibel completed IPO in February 2021 trading on NASDAQ as DBTX until acquisition in 2023. , strengthening the company s gene therapy and auditory programs. Appointments. Decibel Therapeutics equivalents and available-for-sale securities was primarily due to net proceeds of $125. dusyns akbpa njmtq hmbovcy wtgpu ynw lemon hlge thyojxd sciksbv
Top